|
The FDA has approved a label change for the obesity drug Wegovy,
allowing it to be used to reduce the risk of stroke, heart attacks, and
other serious cardiovascular problems in overweight or obese patients.
Based on a study showing its effectiveness in
cutting heart-related risks,
Wegovy is the first medication to receive approval for this purpose,
signaling a significant advancement in public health and potentially
changing how heart patients are treated.
|
Amylyx Pharmaceuticals announced that its ALS drug, Relyvrio, did not
show significant benefit in a large phase 3 clinical trial and may be
withdrawn from the market. Despite gaining FDA approval in September
2022 based on a small phase 2 trial, the drug failed to outperform a
placebo in improving participants' ALS functional scale and overall
survival. Now, discussions are underway about potentially withdrawing
Relyvrio from the market, raising concerns about the drug's effectiveness
and its high cost of about $158,000 per year.
|
Federal regulators have delayed a decision on Eli Lilly's potential
Alzheimer's treatment, donanemab, and have requested an advisory
committee to examine the drug's safety and effectiveness. Eli Lilly
expected the FDA to decide on donanemab's approval by the end of the
month, but the agency's request for additional information has postponed
the decision. Donanemab, if approved, would be the second drug
convincingly shown to delay cognitive decline in Alzheimer's patients,
targeting amyloid plaque buildup in the brain, but it comes with serious
side effects such as brain swelling and bleeding, similar to other
plaque-targeting drugs.
|
Tissue samples from the brain of Robert Card, who killed 18 people in a
shooting rampage in Maine, showed evidence of traumatic brain injury
but not chronic traumatic encephalopathy (CTE), according to the
Concussion Legacy Foundation. Card, a US Army reservist, had been
exposed to low-level blasts during his time at an Army hand grenade
training range, potentially contributing to his brain injury.
|
Florida's Medicaid call center faces significant challenges, with 8 in 10
calls being automatically disconnected, hindering access to health care.
Long wait times and disconnection rates are preventing qualifying families
from renewing or accessing Medicaid coverage, contributing to a drop in
enrollment by 17% since April.
|
|